Q-omics provides the consensus-scored STPG1 profile across patient tissues and cancer cell-line models. STPG1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, STPG1 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, STPG1 RNA expression shows 19,468 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, KICH, and THYM as cancer lineages where STPG1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STPG1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STPG1 survival associations across molecular data types. STPG1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STPG1 RNA expression–survival associations across cancer types. High STPG1 expression shows unfavorable associations in LGG, KICH and GBM, but favorable associations in UVM, KIRC and LUSC. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for STPG1 RNA expression.
This table summarizes STPG1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for STPG1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STPG1 shows lower tumor expression in KICH, KIRC and COAD and higher tumor expression in HNSC, BLCA and LIHC. The KICH box plot shows higher STPG1 RNA expression in normal versus tumor tissue (log2 FC = −1.781, t-test p < 0.001).
This table shows molecular features associated with STPG1 in patient tissues and cancer cell lines. In patient samples, STPG1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, STPG1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SOFT_TISSUE.
